Sufentanil sublingual microtablets (SSMs) at a dose of 15 Hg per tablet have been studied for postoperative patient-controlled analgesia with a 20-minute lockout via a bedside handheld system over 2 days to 3 days of use. For more short-term (G24 hours) management of acute moderate-to-severe pain, such as in the ambulatory surgical setting, a single, higher-strength SSM dose administered via a health care provider would be of benefit as it would require less frequent administration and avoid the setup of a drug delivery system.
S
ufentanil is a highly lipophilic opioid that has a rapid equilibration half-life between plasma and central nervous system effector sites (t 2ke0 = 6 minutes) compared with other opioids, such as morphine (t 2ke0 = 2.8 hours). 1 Sufentanil also benefits from having no active metabolites and a high therapeutic index (lethal dose / effective dose) in preclinical studies. 2 Intravenously administered sufentanil has a short duration of action because of a rapid initial redistribution of 1.4 minutes. 3 This results in a short context-sensitive half-time (CST 2 = time from peak plasma level (C max ) to 50% of C max ) of 15 minutes or less, and therefore, this opioid has had limited use in the postoperative setting. 4, 5 Sufentanil sublingual microtablets (SSMs) have been designed to take advantage of the attributes of sufentanil while using the sublingual route of administration to avoid the initial rapid redistribution from plasma. Administration of SSM (15 Hg) results in a longer CST 2 value of 2.5 hours 4 and has been shown to be effective in the management of moderate-to-severe pain following major joint replacement and open abdominal surgery. 5 The SSM 15-Hg dosage strength has been studied for postoperative patient-controlled analgesia with delivery as frequently as every 20 minutes via a bedside handheld system over 2 days to 3 days of use. 6Y8 For more shortterm (G24 hours) management of acute moderate-to-severe pain, such as in the ambulatory surgical setting, emergency department, or field-based trauma settings, a single, higher-strength SSM dose administered via a health care provider (HCP) would be of benefit because it would require less frequent administration and avoid the setup of a drug delivery system. This dose-finding study was conducted to determine the optimal SSM dosage strength to achieve rapid onset of analgesia in a postoperative ambulatory setting and minimize HCP redosing frequency to no more than once per hour.
PATIENTS AND METHODS
This was a two-center, randomized, double-blind, placebocontrolled, parallel design study with patients randomized to SSM 20 Hg, SSM 30 Hg, or placebo sublingual microtablets. All microtablets were white, 3-mm diameter disc-shaped tablets and identical in appearance. The study was approved by a centralized institutional review board (Copernicus, Durham, NC) and was conducted at Lotus Clinical Research (Pasadena, CA) and Jean Brown Research (Salt Lake City, UT). The study was registered on ClinicalTrials.gov (NCT 01710345).
Sites were requested to recruit equal numbers of male and female adult patients, American Society of Anesthesiologists class I to III, scheduled to undergo primary, unilateral first metatarsal bunionectomy surgery alone or with ipsilateral hammertoe repair. Operative anesthesia was intravenous sedation and a Mayo block with lidocaine. Following surgery, a patient was eligible to begin study treatment once awake, alert, breathing spontaneously (respiratory rate, 8Y24; oxygen saturation 9 95%), and reporting a pain intensity (PI) rating of at least a 4 on an 11-point numeric rating scale of 0 to 10 (0 = no pain, 10 = worst possible pain). Study drug was administered by the study staff to the sublingual space at the patient's request but no more frequently than once per hour. If a patient experienced inadequate analgesia with the study drug, rescue medication, one oral Vicodin tablet (5-mg hydrocodone/500-mg acetaminophen) was allowed 10 minutes after administration of a dose of study drug but not within the first hour of the study and not more frequently than every 4 hours. Patient-reported PI and pain relief (PR) scores were recorded at 15, 30, and 45 minutes after the first dose of study drug and then hourly throughout the 12-hour study period. The double stopwatch technique was used to assess times to perceived and meaningful PR. Vital signs (blood pressure, heart rate, respiratory rate, and oxygen saturation) were recorded at the same time as pain scores. Oxygen saturation was monitored continuously for the entire study period. At the end of the study or at early termination, the patient completed a global assessment of effectiveness and tolerability (poor, fair, good, or excellent). After each dose of study drug, the oral mucosa was checked by study staff for any signs of edema or erythema using the Draize scale. 9 Venous blood samples for analysis of sufentanil concentration were collected at 1, 4, 8, and 12 hours after the first dose of study drug.
The primary efficacy end point was the time-weighted summed PI difference over the 12-hour study period (SPID12). Secondary efficacy measures included time-weighted SPID after a single dose over 1 hour (SPID1), total PR over the 12-hour study period (TOTPAR12), PI, PR, and PI difference (PID) at each evaluation time point, proportion of patients responding in each category of the global assessments, time to perceived and meaningful analgesia, and time to first use of rescue medication.
Patients who met the eligibility requirements were randomized in a 2:2:1 ratio into one of three treatment groups (SSM 20 Hg, SSM 30 Hg, and placebo) within one of two age groups (G65 years and Q65 years) at each study center. An Interactive Response Technology was used to assign a patientspecific randomization number to each eligible randomized patient based on a blinded patient randomization schedule.
Statistical Analysis
Approximately 110 patients were to be randomized to ensure at least 100 patients (40 patients in each SSM group and 20 patients in the placebo group) received study drug and had available primary efficacy data for data analysis. A sample size of 60 patients (40 patients in a SSM group and 20 patients in the placebo group) was based on an effect size of 0.8 for the primary efficacy end point, SPID12. This sample would have 80% power to show a statistical difference at the significance level of 0.05 between two treatment groups.
Efficacy analyses were performed using an intent-to-treat (ITT) population, defined as all randomized patients who received at least one dose of study drug. A parallel lines analysis of covariance model was used for the analysis of the primary efficacy end point, SPID12, as well as continuous secondary efficacy end points derived from the pain assessment data. This analysis of covariance model included treatment and center factors and baseline PI as a covariate. The least squares (LS) mean of each treatment and their 95% confidence interval (CI) were presented. To mitigate the impact of rescue use on efficacy end points, the last observation carried forward method was used to impute prerescue PI and PR scores for 4 hours after rescue was administered for the derivation of efficacy end points based on the pain assessment data. The last observation carried forward imputation method was also used for patients dropping out of the study because of inadequate analgesia, and the worst observation carried forward imputation method was used for patients dropping out because of an adverse event (AE).
For the analysis of the dichotomous outcome data, a twosample Z test on two proportions between each SSM treatment and placebo treatment were performed. The survival analysis method was used to analyze the time-to-event data. KaplanMeier product limit estimators of cumulative rates of patients reaching the event (i.e., time to take first rescue medication, time to perceived PR, and time to meaningful PR) at follow-up time points were calculated. A log-rank test was used to provide overall comparison among treatment groups.
The Medical Dictionary for Regulatory Activities (MedDRA) version 14.0 was used to map each AE verbatim term. Adverse event analyses included all patients who received at least one dose of the study drug. The Fisher's exact test was used to compare the incidence of AEs among treatment groups.
RESULTS
The study enrolled patients from October 2012 to February 2013 at which time projected enrollment was complete. A total of 101 patients were randomized (41 patients to SSM 20 Hg, 40 patients to SSM 30 Hg, and 20 patients to placebo), and 100 patients received treatment and were included in the ITT population for analysis. One patient randomized to SSM 20 Hg did not receive treatment because of oxygen scavenger residue in the bottle of study drug (see Figure 1 for the CONSORT flow diagram for study patient disposition).
The mean (SD) age of the ITT population was 42.5 (12.6) years, and 96 (96.0%) patients were younger than 65 years. Overall, 51 patients (51.0%) were male, and 71 (71.0%) were white. There were no statistically significant differences among treatment groups for any demographic or baseline variables (Table 1) .
Efficacy
The mean baseline PI for the ITT population was not significantly different among treatment groups. The SSM 30-Hg group was superior to placebo ( p = 0.003) for the primary end point, SPID12, with LS mean scores of 6.53 versus j7.12, respectively ( Table 2 ). The result for the SSM 20-Hg group was not significantly different from the placebo group.
The summed PI over 1 hour, SPID1, was assessed to determine the efficacy of a single dose of SSM, since no rescue medication or redosing of study drug was allowed during this period. Only the SSM 30-Hg group was superior to placebo for the SPID1 ( p G 0.001). LS mean scores of the SPID1 for the SSM 30-Hg group and placebo were 1.64 and 0.15, respectively (Table 2) . Single-dose SSM efficacy is demonstrated in Figure 2 of SPID by evaluation time point over the first hour, Table 2 ). The SSM 30 Hg was superior to placebo for the secondary efficacy end points PI, PID and PR for most evaluation time points throughout the study. Significant differences between the SSM 30-Hg group and placebo for SPID and TOTPAR were generally apparent within 30 minutes and continued until the end of the 12-hour treatment period. Significant differences between SSM 30-Hg group and placebo for PI, PID, and PR were generally apparent within 30 minutes and continued for approximately 4 hours to 5 hours and then again at 10 hours to 11 hours.
The double stopwatch method was used to assess perceived and meaningful PR. There was a statistically significant difference for the SSM 30-Hg group versus placebo for the median time to perceived PR (24 minutes, p = 0.023) and median time to meaningful PR (74 minutes, p = 0.010). There was no statistical significance for these comparisons in the SSM 20-Hg group versus placebo.
Ten percent (4 of 40) of the patients in the SSM 20-Hg group and 43.6% (17 of 39) of the patients in the SSM 30-Hg group responded ''good'' or ''excellent'' on the patient global assessment for the effectiveness, compared with 5.0% (1 of 20) of the patients in the placebo group. The difference between SSM 30 Hg versus placebo was statistically significant ( p = 0.002).
The number of doses of study drug used and the interdosing interval are shown in Table 2 . There was no statistically significant difference among treatment groups.
There was statistically lower requirement for rescue doses of Vicodin in the SSM 30-Hg group ( p G 0.001; mean, 1.8, 1.1, and 2.1 tablets for the SSM 20 Hg, SSM 30 Hg, and placebo groups, respectively; Table 2 ). There was also a statistically significant difference for the SSM 30-Hg group versus placebo in cumulative event rates for time to take first rescue medication due to inadequate analgesia after study drug administration ( p G 0.001) with median times for SSM 30 Hg, SSM 20 Hg, and placebo groups of 320, 187, and 129 minutes, respectively. There was no statistical significance for the SSM 20 Hg versus placebo comparison.
Safety
A total of 58 patients (58.0%) had a total of 135 AEs during the study. Two SSM 20 HgYtreated patients had serious AEs (SAEs), reported 8 days and 11 days after the 12-hour study period. These SAEs (both infections of the foot) were assessed as not related to the study drug by the study investigator. All AEs were mild or moderate in severity with the exception of two patients. One patient (SSM 30-Hg group) had an AE of decreased respiratory rate that was judged as severe and probably related to the study drug. Oxygen saturation did not decrease below 95% and no treatment for this AE was required but the patient discontinued study drug. The patient also had an AE of sedation that was judged as moderate and probably related to the study drug. An additional patient (SSM 20-Hg group) had osteomyelitis of the foot that was judged to be severe and not related to the study drug; this was also classified as an SAE as mentioned earlier.
Two patients in the 30-Hg group each had two AEs that resulted in the discontinuation of study drug. One patient dropped out because of decreased respiratory rate and also had sedation as described earlier. A second patient dropped out because of AEs of moderate worsening anxiety and moderate chest discomfort, both of which were assessed as not related to the study drug. There were no statistically significant differences among treatment groups for the proportion of patients with any AE causing discontinuation of study drug.
The most frequently reported related AEs for all patients were nausea (37%), vomiting (17%), dizziness (12%), and somnolence (10%). All related AEs were similar in occurrence among the three treatment groups with the exception of nausea, vomiting, and somnolence, which demonstrated an SSM dosedependent increase in rates of occurrence (Table 3) .
Vital Signs
At various time points throughout the study, there were statistically significant ( p G 0.05) vital sign changes that were small and considered not clinically significant. Compared with baseline, mean systolic blood pressure increased by up to 8 mm Hg for placebo; diastolic blood pressure decreased by up to j4 mm Hg for SSM 20 Hg and SSM 30 Hg. For heart rate, there were small mean decreases (less than j4 beats per minute) and increases (3.8 beats per minute) from baseline in the SSM 30-Hg group. Respiratory rate had mild decreases in the SSM 20-Hg and SSM 30-Hg groups (less than j1.4 breaths per minute) and mild increases (less than 1.8 breaths per minute) in the placebo group. For oxygen saturation, there were small decreases in all groups (all j1.3% or less).
The sublingual tissue evaluation of erythema and edema was performed after administration of each microtablet. Two patients (5.0%) in the 20-Hg group and one patient (5.0%) in the placebo group experienced very slight erythema. No patients experienced edema.
Sufentanil Plasma Concentrations
Mean (SD) plasma sufentanil concentrations for patients in the SSM 30-Hg group at 1 hour, 4 hours, 8 hours, and 12 hours were 44.8 (19.0) pg/mL, 46.1 (27.8) pg/mL, 51.2 (29.5) pg/mL, and 50.2 (35.7) pg/mL, respectively. Mean (SD) plasma sufentanil concentrations for patients in the SSM 20-Hg group at 1 hour, 4 hours, 8 hours, and 12 hours were 22.1 (11.9) pg/mL, 32.5 (17.6) pg/mL, 33.1 (16.6) pg/mL, and 29.7 (21.3) pg/mL, respectively.
DISCUSSION
Currently, there is no high-potency oral transmucosal opioid available for the management of moderate-to-severe acute pain in the nonopioid tolerant patient. The advantage of lipophilic opioids, such as sufentanil, is the enhanced transmucosal delivery followed by rapid plasmaYcentral nervous system equilibration, which allows a noninvasive route of delivery to have a rapid onset of analgesia. 1, 4, 5, 10, 11 Furthermore, this route of delivery ameliorates the limiting issue with intravenous administration of these lipophilic compounds, namely, rapid redistribution producing a short CST 2 . Sublingual delivery of sufentanil also avoids the common pitfall of intramuscular administration of morphine in acute trauma settings, such as battlefield injuries. Patients in these settings often have poorly perfused muscles due to hypovolemia, resulting in poor systemic uptake of intramuscular morphine. Repeated intramuscular injections of morphine to overcome this limitation can result in tragic consequences due to dose-stacking once volume resuscitation occurs. Since carotid artery perfusion is preferentially maintained during hypovolemia, sublingual uptake of drug is relatively unaffected during states of shock, allowing reliable onset and maintenance of analgesia for the patient and avoiding dose stacking.
The results of this dose-finding study demonstrate, from both an efficacy and a safety perspective, that the 30-Hg SSM dose strength is the appropriate dose to advance into later stage clinical testing, since the goal with powerful opioid analgesics is to determine the least effective dose and use a variable redosing interval to titrate to each patient's specific analgesic requirements. Both single-dose efficacy (SPID1) and repeatdose efficacy (SPID12) demonstrated superiority to placebo for the SSM 30 Hg, whereas the SSM 20 Hg showed no difference to placebo. Time to perceived analgesia for the 30-Hg SSM was rapid (24 minutes), and time to meaningful analgesia occurred just slightly after the 1-hour minimum redosing interval of the drug (74 minutes). Within 30 minutes, the SSM 30 Hg PID was statistically greater than placebo and achieved a value greater than 1.3, which has been shown to be a clinically meaningful PID for analgesics in acute pain settings. 12 These analgesia onset data suggest that many patients can achieve rapid analgesia with a single SSM 30-Hg dose. Furthermore, the goal of achieving an average interdosing interval sufficiently long enough to avoid overburdening the HCP and minimize analgesic gaps for the patient, while still allowing for safe opioid titration, seems also to have been achieved with the 30-Hg SSM dose strength. The average interdosing interval for SSM 30 Hg was 145 minutes, which allows for a significant duration of analgesia in the average patient, while the 1-hour minimum redosing interval allows for patients who require more frequent dosing.
The conduct of placebo-controlled trials in patients experiencing experiences moderate-to-severe pain is always challenging. For ethical reasons, open-label rescue analgesics must be made available, in this case Vicodin every 4 hours as needed for inadequate analgesia. Since patients are never sure if they are receiving active or placebo treatment, any flare in the patient's pain 
